The FDA has shortened the recommended post-infusion observation for Amgen’s Imdelltra to 6–8 hours after each of the first two doses for adults with ES-SCLC who progressed after platinum chemotherapy. The label still requires a day-after vital-sign check following those initial infusions. Monitoring times for later cycles remain unchanged, and patients must stay within one hour of medical facilities for 48 hours after the first- and eighth-day infusions. Amgen says the change may reduce time spent in clinical settings and improve access to care.
FDA Cuts Post-Infusion Monitoring Time for Amgen’s Imdelltra, Easing Early Treatment Burden
Imdelltra is a targeted immunotherapy designed to bind to DLL3 proteins
The US Food and Drug Administration has approved an update to the prescribing information for Amgen’s Imdelltra (tarlatamab-dlle), shortening the recommended post-infusion observation period after the therapy’s first two doses for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease progressed following platinum-based chemotherapy.
What Changed
Under the revised label, patients should be monitored for six to eight hours in an appropriate healthcare setting after each of the first two infusions, replacing the prior 22 to 24 hours of observation. The label also requires a follow-up assessment, including vital signs, on the day after each of those first two doses.
Monitoring For Subsequent Doses
- Third dose and throughout Cycle 2: 6–8 hours
- Cycles 3 and 4: 3–4 hours
- Cycle 5 and beyond: 2 hours
The updated label continues to advise that patients remain within one hour of suitable medical facilities for 48 hours from the start of the first- and eighth-day infusions and be accompanied by a caregiver during that period.
"This approval is an important step in simplifying care for people living with and treating ES-SCLC," said Jay Bradner, Amgen’s Executive Vice President for AI and Data Research and Development. "Reducing monitoring to six to eight hours for the initial doses may help address practical barriers associated with administering Imdelltra and enable more patients to receive care closer to home."
Amgen said the label change could reduce time patients spend in healthcare settings during the early phase of treatment and that it will work with providers, patients and care partners to provide educational support for navigating Imdelltra treatment.
About Imdelltra
Imdelltra is a targeted bispecific immunotherapy designed to bind DLL3 proteins on tumor cells and CD3 on T cells, recruiting and activating the immune system to attack small cell lung cancer cells. The monitoring update applies only to the first two infusions.
Separately, in January 2025 Amgen obtained conditional approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Imdelltra as a treatment for ES-SCLC.
Help us improve.
